PharmaDossier
PHARMApharmadossierPharmaDossier
Pricing & Access

GLP-1 insurance coverage 2026: major payer guide

Cross-payer GLP-1 coverage for 2026: PA criteria, formulary tiers, BMI thresholds, and cost-sharing at Aetna, BCBS, Cigna, CVS Caremark, Express Scripts, UnitedHealthcare, Medicare, and Medicaid.

Ran Chen
Ran Chen
15 min read · Published · Source-cited

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) — are among the most prescribed and most expensive drug classes in the United States. In 2026, payer coverage is in active flux: some commercial plans are expanding access to weight-loss GLP-1s, while others are excluding them entirely. Medicare is launching a demonstration program for limited GLP-1 access starting July 2026. Medicaid programs in several states have cut weight-loss GLP-1 coverage effective January 2026.

This guide is for market access teams, benefit verification specialists, prescribers, and hub-services operators who need to navigate the current payer landscape. It compares coverage rules, prior authorization criteria, formulary tiers, and cost-sharing across the five largest commercial insurers and PBMs, plus Medicare and Medicaid — using primary source documents from each payer.

Quick answer

Payer / PBM Weight-loss GLP-1s (Wegovy, Zepbound) Diabetes GLP-1s (Ozempic, Mounjaro) Key PA criteria Notable 2026 change
Aetna (CVS Health) Covered on most commercial group plans with PA Covered for T2D with PA BMI ≥30 (or ≥27 + comorbidity); 6-month documented weight-loss attempt; lifestyle program Zepbound added to preferred tier on additional commercial plans; Medicare Advantage GLP-1 weight-loss coverage starts July 2026
BCBS (varies by plan) Coverage dropping on many fully insured and individual plans; some employer plans still cover Covered for T2D with PA Varies by affiliate; typical: BMI ≥30, lifestyle documentation, step therapy BCBS of Massachusetts excluding Wegovy, Saxenda, Zepbound upon plan renewal starting Jan 2026
Cigna (Evernorth) Covered on some commercial plans with PA Covered for T2D with PA BMI ≥30 (or ≥27 + comorbidity); 3-month lifestyle program; step therapy may apply Wegovy high-dose added to PA list June 2026; Express Scripts Patient Assurance Program expanding to GLP-1 weight-loss drugs
CVS Caremark Covered on template formularies if plan sponsor elects; Zepbound reintroduced Oct 2026 Covered Plan-dependent; typical BMI and lifestyle criteria Zepbound returning to commercial formularies Oct 2026; Foundayo new-to-market block removed June 2026
Express Scripts Coverage depends on employer/plan sponsor election; excluded from National Preferred Formulary weight-loss class Covered for T2D PA, quantity limits, step therapy per plan Adding Wegovy and Zepbound to Patient Assurance Program later in 2026
UnitedHealthcare Covered on many commercial plans with PA (Program 2026 P 1114-20) Covered for T2D with PA BMI ≥30 (or ≥27 + comorbidity); lifestyle modification; Wegovy also for MASH Tier 4–5 specialty; reauthorization requires ≥4% weight loss for Wegovy/Zepbound
Kaiser Permanente Plan-dependent; some regions excluding weight-loss GLP-1s Covered for T2D Varies by region and plan type Multiple BCBS-style exclusions rippling through integrated health plans
Medicare Part D Not covered for weight loss (federal exclusion); Wegovy covered for CV indication; GLP-1 Bridge demo starts July 2026 Covered for T2D with PA Indication-specific criteria vary by Part D plan CMS GLP-1 Bridge demonstration: July 2026–Dec 2027, operates outside Part D benefit
Medicaid Many states cutting weight-loss GLP-1 coverage in 2026; varies by state Generally covered for T2D State-specific Medi-Cal excluded GLP-1s for weight loss effective Jan 1, 2026; Wegovy retained for MASH and CV

Who this is for

This guide is written for:

  • Market access and payer strategy teams at pharmaceutical manufacturers
  • Benefit verification and prior authorization specialists at specialty pharmacies and hub services
  • Prescribers (endocrinologists, obesity medicine specialists, primary care) who need to anticipate payer requirements
  • Employer benefit consultants evaluating GLP-1 coverage design

This is not medical advice or reimbursement guidance for a specific patient or plan.

Source standard

Coverage rules change frequently. Every fact in this guide is sourced from payer policy documents, formulary files, CMS guidance, or trade reporting dated 2025–2026. Always verify current-year formulary and PA criteria on the specific plan's member portal or provider portal before submitting authorization.

Aetna (CVS Health)

Formulary positioning

Aetna manages pharmacy benefits through CVS Caremark. As of the 2026 plan year:

  • Wegovy and Zepbound are covered on most commercial group plans with prior authorization. Zepbound was added to preferred-tier coverage on additional commercial plans for 2026, narrowing the PA gap between Wegovy and Zepbound.
  • Ozempic and Mounjaro are covered for type 2 diabetes with prior authorization and a documented diagnosis.
  • Individual marketplace (ACA) plans have more limited GLP-1 coverage. Some Aetna exchange plans exclude GLP-1s for weight loss while covering medications like Contrave or Qsymia.
  • Small group AFA level-funded plans generally exclude weight-loss medication coverage.

Prior authorization criteria (Aetna CPB 0784)

Aetna's clinical policy bulletin for GLP-1 weight-loss medications requires:

  1. BMI threshold: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
  2. Documented weight-loss attempt: At least 6 months of a structured weight management program, which may include a diet program, behavioral counseling, or a prior medication trial. Note: Aetna increased this from 3 months to 6 months on many 2025–2026 plans.
  3. Prescriber requirements: Licensed physician or advanced practice provider; some plans require a specialist referral
  4. Ongoing lifestyle program: Participation in a lifestyle modification program concurrent with GLP-1 therapy

Cost-sharing

Typically $25–$100/month after PA approval, depending on specific plan tier and formulary position.

Medicare Advantage

Aetna Medicare Advantage plans will begin covering Wegovy and Zepbound for weight loss with prior authorization starting July 2026, per a new CMS rule that expands GLP-1 access in Medicare Advantage and Medicaid.

Blue Cross Blue Shield (varies by licensee)

BCBS is not a single national payer — it is a federation of independent licensees, and GLP-1 coverage varies dramatically by plan, state, and employer group. This is the most fragmented payer landscape for GLP-1s.

Coverage trend: narrowing

Several major BCBS licensees have announced exclusions or restrictions on GLP-1 weight-loss coverage effective 2026:

  • BCBS of Massachusetts: Starting January 1, 2026 (upon plan renewal), Wegovy, Saxenda, and Zepbound are excluded from coverage for weight loss. Coverage for GLP-1s approved for type 2 diabetes (Ozempic, Mounjaro, Trulicity) is unchanged. This exclusion is a benefit design change, not a medical-necessity determination, and cannot be appealed. Optional coverage may be purchased by employer groups with 100+ employees.
  • Anthem BCBS (Elevance Health): In California, all GLP-1 drugs were reclassified to Tier 4 specialty as of January 2025 and remain non-formulary with PA required. Claims that were previously overridden are now being denied as plan exclusions. Other Anthem BCBS markets vary.
  • Harvard Pilgrim Health Care (a Point32Health company): Introduced EncircleRx program effective January 1, 2026, requiring BMI ≥32 (or ≥27 with two weight-related comorbidities) and mandatory enrollment in a 9amHealth virtual weight management program. All existing GLP-1 authorizations required re-authorization.
  • BCBS of Illinois: Available on select employer plans; requires 6-month documented lifestyle intervention and step therapy (Contrave before GLP-1).
  • BCBS of Texas: Limited coverage; employer-dependent; BMI ≥30 and 3-month lifestyle modification documented.
  • BCBS of Vermont / VEHI: Excluding GLP-1s for weight loss starting January 2026, retaining coverage only for T2D and cardiovascular indications.

Prior authorization criteria (typical)

Criterion Common requirement
BMI ≥30, or ≥27 with qualifying comorbidity
Lifestyle documentation 3–6 months structured program
Step therapy Contrave or Saxenda trial before Wegovy/Zepbound on many plans
Reauthorization Documented weight loss (typically ≥5%)

Cigna / Evernorth

Formulary positioning

Cigna's pharmacy benefit is managed by Evernorth (which includes Express Scripts). Key 2026 changes:

  • Wegovy high-dose added to prior authorization list effective June 2026
  • Zepbound pens remain on formulary with PA on most commercial plans
  • Zepbound vials are excluded from the 2026 Express Scripts National Preferred Formulary (preferred alternatives: liraglutide, Wegovy injection, Wegovy tablets, Zepbound pens)

Prior authorization criteria

Cigna's PA for GLP-1 weight-loss medications typically requires:

  1. BMI threshold: ≥30, or ≥27 with qualifying comorbidity
  2. Lifestyle program: At least 3 months of a structured lifestyle modification program
  3. Step therapy: Some plans require a trial of Contrave or another lower-cost weight-loss medication before approving a GLP-1
  4. Inadequate response: Documentation that lifestyle changes alone were insufficient

Patient Assurance Program

Express Scripts (part of Evernorth) is expanding its Patient Assurance Program to include GLP-1 weight-loss drugs (Wegovy and Zepbound) later in 2026, following agreements with Lilly and Novo Nordisk. This program offers reduced out-of-pocket costs for eligible members.

CVS Caremark

Formulary positioning

On May 28, 2026, CVS Caremark announced significant updates to its commercial formularies:

  • Zepbound will be added back to commercial formularies as an additional preferred option effective October 1, 2026
  • Foundayo (orforglipron) new-to-market block will be removed effective June 1, 2026, where plans approve coverage
  • Plan sponsors that adopt CVS Caremark template formularies retain discretion to customize GLP-1 coverage

Coverage model

CVS Caremark's approach emphasizes affordability management:

  • Prior authorization helps ensure clinically appropriate coverage
  • Formulary strategy aims to make medications more affordable for plan sponsors
  • Optional CVS Weight Management program supports sustained weight loss alongside GLP-1 therapy

Express Scripts

National Preferred Formulary

Express Scripts' 2026 National Preferred Formulary (NPF) positions weight-loss GLP-1s under indication-based management:

  • Preferred: Zepbound pens (with PA)
  • Excluded: Zepbound vials; liraglutide (generic) remains a lower-cost alternative
  • Wegovy injection and Wegovy tablets are on the formulary with PA
  • Coverage for weight-loss GLP-1s ultimately depends on the employer or plan sponsor's benefit design

TRICARE

Express Scripts manages the TRICARE pharmacy benefit. As of August 31, 2025:

  • Weight-loss medications (Wegovy, Zepbound, Contrave, Qsymia, phentermine) are covered for TRICARE Prime and TRICARE Select beneficiaries with approved PA
  • Coverage is no longer available for non-Prime and non-Select beneficiaries

UnitedHealthcare

Formulary positioning

UnitedHealthcare places GLP-1 agonists on Tier 4 (specialty) or Tier 5 (non-preferred specialty), which carries higher copay or coinsurance. The 2026 clinical pharmacy program (Program 2026 P 1114-20) governs PA.

Prior authorization criteria (UHC 2026)

For Wegovy injection, Wegovy tablets, and Zepbound:

  1. Diagnosis: Treatment for appetite suppression or weight loss, OR Wegovy for MASH (metabolic dysfunction-associated steatohepatitis)
  2. BMI threshold: ≥30, or BMI ≥27 with a weight-related comorbidity (dyslipidemia, hypertension, T2D, sleep apnea), OR BMI >95th percentile for pediatric patients
  3. Lifestyle modification: Must be used as an adjunct to dietary/caloric restriction, exercise, behavioral support, or community-based program
  4. Reauthorization: Requires documented weight loss of ≥4% of baseline body weight
  5. Authorization duration: 5 months for initial authorization; 12 months for reauthorization

Reauthorization traps

  • Baseline weight must be documented at the time the medication is started
  • Failure to document baseline weight can lead to renewal denials
  • UHC compares renewal weight to original starting weight

Kaiser Permanente

Kaiser Permanente's integrated model means formulary decisions vary by region. In 2026:

  • GLP-1 coverage for T2D continues with PA
  • Weight-loss GLP-1 coverage is increasingly restricted, following broader market trends
  • Members should verify coverage through their specific Kaiser region's formulary

Medicare

Current law: weight-loss exclusion

Under federal law, Medicare Part D cannot cover drugs used for "anorexia, weight loss, or weight gain." However:

  • Wegovy is covered when prescribed for cardiovascular risk reduction in adults with established cardiovascular disease and obesity
  • Ozempic, Mounjaro, and other T2D GLP-1s are covered under Part D for type 2 diabetes with plan-specific PA

CMS Medicare GLP-1 Bridge demonstration

CMS announced the Medicare GLP-1 Bridge, a short-term demonstration running July 1, 2026, through December 31, 2027:

  • Provides eligible Medicare Part D beneficiaries access to certain GLP-1 drugs
  • Operates outside of the Part D benefit's coverage and payment flow
  • Part D sponsors do not carry risk for eligible GLP-1 drugs under the Bridge
  • Part D sponsors do not need to opt in for eligible beneficiaries to access drugs
  • CMS uses a single central processor for PA, claims adjudication, and pharmacy payment

This is the largest expansion of GLP-1 access in Medicare's history, though it is a time-limited demonstration, not a permanent benefit change.

Medicare Advantage

Starting July 2026, Medicare Advantage plans can begin covering GLP-1s for weight loss under new CMS authority. Aetna and other MA carriers are expected to implement coverage with PA requirements.

Medicaid

Medicaid GLP-1 coverage varies by state and is rapidly changing:

States restricting weight-loss GLP-1 coverage in 2026

  • California (Medi-Cal): Effective January 1, 2026, Medi-Cal excluded GLP-1s for weight loss. Wegovy is retained for MASH and cardiovascular indications with PA. Zepbound and Saxenda excluded for weight loss only. T2D GLP-1s continue with diagnosis code requirement. Members under 21 retain coverage under EPSDT requirements.
  • Pennsylvania: Weight-loss-only GLP-1 coverage restricted as of early 2026. CV and other approved indications continue with PA.
  • Illinois: Wegovy not listed on the 2026 Illinois Medicaid PDL; coverage uncertain.
  • North Carolina: NC Medicaid GLP-1 coverage requires PA with specific criteria.

Federal EPSDT protection

For Medicaid members under age 21, federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) requirements mean that GLP-1s for weight loss may continue to be covered if medically necessary, even in states that restrict adult coverage.

Key prior authorization pitfalls

Based on payer policy documents and specialty pharmacy operational data:

  1. Wrong indication code: The most common cause of denial. Submitting under obesity (E66.01) when the patient has T2D (E11.9) routes to the wrong PA pathway. Always verify which indication code the plan expects.
  2. Insufficient lifestyle documentation: Most commercial plans require 3–6 months of documented lifestyle modification. Vague notes ("patient advised to diet and exercise") are frequently rejected.
  3. Missing baseline weight: UHC and other payers require documented baseline weight at GLP-1 initiation. Without it, reauthorization is at risk.
  4. Step therapy not completed: Plans requiring a Contrave or Saxenda trial before Wegovy/Zepbound will deny if step therapy is not documented.
  5. Plan exclusion vs. PA denial: Some BCBS plans have benefit-level exclusions for weight-loss GLP-1s. These cannot be appealed through medical necessity pathways.
  6. Continuation of therapy: When a patient changes insurance, the new plan may not honor the prior plan's authorization. Submit as "continuation of therapy" with prior response documentation.

What to watch

  • CMS GLP-1 Bridge implementation: Watch for PA criteria, eligible drug list, and pharmacy enrollment starting July 2026
  • CVS Caremark Zepbound reintroduction: October 2026 formulary change may shift competitive dynamics between Wegovy and Zepbound
  • BCBS exclusions cascading: Additional BCBS licensees may follow Massachusetts and Vermont in excluding weight-loss GLP-1s
  • Express Scripts Patient Assurance expansion: GLP-1 weight-loss drugs joining the program later in 2026 could lower out-of-pocket costs
  • Foundayo (orforglipron) oral GLP-1: CVS Caremark removing new-to-market block June 2026; payer uptake of the first oral GLP-1 will shape the competitive landscape
  • State Medicaid policy changes: Additional states likely to restrict weight-loss GLP-1 coverage in 2026–2027 as budget pressures mount
  • Employer plan design: Self-funded employers ultimately decide GLP-1 coverage; a 2025 KFF survey found that 43% of firms with 5,000+ employees now cover GLP-1s for weight loss, up from 28% in 2024. Monitor annual enrollment materials for 2027 plan changes.
  • Medicare BALANCE model: CMS has delayed the BALANCE model launch for Medicare Part D, which was originally scheduled for January 2027. CMS instead extended the Medicare GLP-1 Bridge through December 31, 2027 to maintain beneficiary access while it collects additional data. The Medicaid portion of the BALANCE model is proceeding on schedule, with state participation starting May 2026 through January 2027. Watch for CMS updates on whether and when the Part D BALANCE model will launch.
  • Electronic prior authorization (ePA): The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), effective January 1, 2026, requires Medicare Advantage and Medicaid managed care plans to implement 72-hour expedited PA decisions and 7-calendar-day standard decisions. By January 1, 2027, these payers must implement FHIR-based PA APIs. This should streamline GLP-1 authorization timelines.

Sources

Topics
GLP-1Payer CoveragePrior AuthorizationCommercial PayerMedicareMedicaidPBMSpecialty DrugsCoverage Access
Ran Chen
Contributing Editor
Ran Chen

Founder, PharmaDossier. Life-sciences operator covering market access, specialty pharma, biosimilars, and regulated healthcare growth.

Follow on LinkedIn →

Keep reading from Pricing & Access

See all →
Pipeline · 10 min read

NASP PDUFA preview: anti-drug antibody strategy for uncontrolled gout

Preview of the June 27, 2026 FDA decision on NASP (sirolimus + pegadricase) for uncontrolled gout: DISSOLVE I and II phase 3 data, access...

Pricing & Access · 9 min read

Trulicity coverage guide: formulary tiers, prior authorization, and patient assistance

Guide to Trulicity coverage for type 2 diabetes and cardiovascular risk reduction, including formulary placement, PA criteria, Medicare,...

Approvals · 9 min read

Xocova (ensitrelvir) access guide: first oral COVID post-exposure prophylaxis

Access guide for Xocova, the first oral antiviral for COVID-19 post-exposure prophylaxis, with SCORPIO-PEP evidence, prior authorization, payer...